Ginseng, American

Summary

Ginseng, American (CHEMBL2109196) is a phase-3 clinical-stage unknown; indicated across 11 conditions including hypertensive disorder and hyperglycemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 11 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109196
Name	Ginseng, American
Type	Unknown
Max phase	3

Also known as: AFX-02, AFX-2, American ginseng, American ginseng root, American ginseng whole, Aralia quinquefolia, Aralia quinquefolia root, Ginseng (panax quinquefolius), Ginseng quinquefolium root, Ginseng, american, north american

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	3	MONDO:0005044	EFO:0000537
hyperglycemia	3	MONDO:0002909	HP:0003074
neoplasm	3	MONDO:0005070	EFO:0000616
leukemia	2	MONDO:0005059	EFO:0000565
AIDS	2	MONDO:0012268	EFO:0000765
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148
multiple sclerosis	2	MONDO:0005301	MONDO:0005301
breast neoplasm	2	MONDO:0021100	MONDO:0007254
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	3
PHASE1	2
Not specified	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06395441	PHASE3	RECRUITING	Wisconsin Ginseng for Decreasing Cancer Related Fatigue
NCT00367926	PHASE3	COMPLETED	The Effect of American Ginseng Root and Its Components on Glycemia in Healthy Individuals
NCT00719563	PHASE3	COMPLETED	American Ginseng in Treating Patients With Fatigue Caused by Cancer
NCT00631852	PHASE2	COMPLETED	A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer
NCT00752895	PHASE2	COMPLETED	American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL
NCT00965822	PHASE2	COMPLETED	A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population
NCT01500096	PHASE2	COMPLETED	American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial
NCT02806349	PHASE2	COMPLETED	Konjac-Glucomannan Fibre Blend and American Ginseng in Type 2 Diabetes
NCT01136928	PHASE1	COMPLETED	Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers
NCT01456182	PHASE1	WITHDRAWN	Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
NCT03407716	EARLY_PHASE1	COMPLETED	Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
NCT00182780	Not specified	COMPLETED	American Ginseng in Treating Patients With Cancer-Related Fatigue
NCT03730298	Not specified	UNKNOWN	American Ginseng for the Prevention of Moderate-severe Fatigue in Breast Cancer Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).